Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Liquidia Corporation (NASDAQ: LQDA) announced that CEO Damian deGoa will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. The presentation will be virtual and available on-demand in the Investors section of Liquidia's website starting at 7:00 a.m. ET on September 13, 2021. It will remain accessible for 30 days post-conference. Liquidia focuses on the development of products for pulmonary hypertension using its PRINT® Technology.
Details
News Market Reaction – LQDA
The recorded move for LQDA in the trading session of this news was -1.81%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MORRISVILLE, N.C., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a virtual format.
The presentation will be available on-demand in the Investors section of Liquidia’s website at https://liquidia.com/investors/events-and-presentations starting at 7:00 a.m. ET on Monday, September 13, 2021, and available for 30 days following the conference.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies is developing LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for rare disease pharmaceutical products, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information
Media & Investors:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.